Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as CLBS03 Low Dose
CLBS03 · 1 trial · 1 indication
The area-under-curve of sequential C-peptide concentrations (AUC-Cpep) during the mixed-meal tolerance test (MMTT) is the gold-standard method to assess residual beta-cell (ie, insulin) secretion in type 1 diabetes.
| Arm | Type | Description |
|---|---|---|
| CLBS03 Low Dose | EXPERIMENTAL | A single infusion of CLBS03 Low Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP (United States Pharmacopoeia) infusion solution. |
| CLBS03 High Dose | EXPERIMENTAL | A single infusion of CLBS03 High Dose, a cell product comprised of autologous, ex vivo expanded regulatory T-cells resuspended in sterile USP infusion solution. |
| Placebo | PLACEBO_COMPARATOR | A single infusion of placebo, consisting of the infusion solution only |
| Name | Type | Description |
|---|---|---|
| CLBS03 Low Dose | BIOLOGICAL | - |
| CLBS03 High Dose | BIOLOGICAL | - |
| Placebo | BIOLOGICAL | - |
Inclusion Criteria: * Male and females aged 8 to 17 years of age * Diagnosis of T1DM within 100 days of receipt of study drug * Positive for at least one islet cell autoantibody * Peak MMTT-stimulated C-peptide level \> 0.2 pmol/mL (at the screening visit) * Weight of ≥30 kg * Must agree to use a r...
CLBS03 is an investigational biologic developed by Lisata Therapeutics, Inc. for diabetes mellitus. It is a Phase 2 cell therapy candidate studied in adolescents with recent onset type 1 diabetes. CLBS03 is also known as CLBS03 Low Dose.
CLBS03 was studied for the treatment of type 1 diabetes in adolescents with recent onset disease. Its Phase 2 trial enrolled patients aged 8 years and older in the United States to evaluate safety and efficacy in this population.
CLBS03 is developed by Lisata Therapeutics, Inc., which trades under the ticker LSTA. The company sponsored the Phase 2 clinical program evaluating CLBS03 in adolescents with recent onset type 1 diabetes.
CLBS03 is in Phase 2 development and is investigational. Its single Phase 2 trial, the Sanford Project T-Rex Study, has been completed. CLBS03 has not been established as an approved therapy.
CLBS03 has been evaluated in one clinical trial, NCT02691247, titled Safety and Efficacy of CLBS03 in Adolescents With Recent Onset Type 1 Diabetes (The Sanford Project T-Rex Study). The Phase 2 trial was completed and enrolled 113 participants in the United States.
Yes, CLBS03 Low Dose is an alternative name for CLBS03. Readers searching either name are referring to the same investigational Lisata Therapeutics biologic being studied in type 1 diabetes.